The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Precision cancer tests encompass imaging and in vitro diagnostic (IVD) products and procedures that directly detect malignancies in patient samples or in the patients themselves.
The global Precision Cancer Diagnostic Tests market was valued at US$ 4148 million in 2023 and is anticipated to reach US$ 9769.5 million by 2030, witnessing a CAGR of 12.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Precision Cancer Diagnostic Tests, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Precision Cancer Diagnostic Tests.
Report Scope
The Precision Cancer Diagnostic Tests market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Precision Cancer Diagnostic Tests market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Precision Cancer Diagnostic Tests companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Abbott Laboratories
- Agilent Technologies
- Becton Dickinson and Company
- Bio-Rad Laboratories
- Biocartis N.V.
- Biocept
- bioMerieux SA
- Canon Medical Systems Corporation
- Cynvenio Biosystems
- Danaher Corporation
- Epigenomics AG
- Exosome Diagnostics
- Foundation Medicine
- General Electric Company
- Genomic Health
- Hologic
- Illumina
- Menarini Silicon Biosystems SpA
- Myriad Genetics
- NanoString Technologies
- Ortho Clinical Diagnostics
- QIAGEN N.V.
- Randox Laboratories Ltd.
- Roche Holding AG
- Royal Philips N.V.
- Siemens AG
- Thermo Fisher Scientific
- Vela Diagnostics
Segment by Type
- Imaging
- Molecular
- Histology/Cytology
- Tumor Marker Immunoassays
- POC Colon Cancer Tests
Segment by Application
- Hospital
- Clinic
- Other
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Precision Cancer Diagnostic Tests companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Precision Cancer Diagnostic Tests Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Imaging
1.2.3 Molecular
1.2.4 Histology/Cytology
1.2.5 Tumor Marker Immunoassays
1.2.6 POC Colon Cancer Tests
1.3 Market by Application
1.3.1 Global Precision Cancer Diagnostic Tests Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Precision Cancer Diagnostic Tests Market Perspective (2019-2030)
2.2 Precision Cancer Diagnostic Tests Growth Trends by Region
2.2.1 Global Precision Cancer Diagnostic Tests Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Precision Cancer Diagnostic Tests Historic Market Size by Region (2019-2024)
2.2.3 Precision Cancer Diagnostic Tests Forecasted Market Size by Region (2025-2030)
2.3 Precision Cancer Diagnostic Tests Market Dynamics
2.3.1 Precision Cancer Diagnostic Tests Industry Trends
2.3.2 Precision Cancer Diagnostic Tests Market Drivers
2.3.3 Precision Cancer Diagnostic Tests Market Challenges
2.3.4 Precision Cancer Diagnostic Tests Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Precision Cancer Diagnostic Tests Players by Revenue
3.1.1 Global Top Precision Cancer Diagnostic Tests Players by Revenue (2019-2024)
3.1.2 Global Precision Cancer Diagnostic Tests Revenue Market Share by Players (2019-2024)
3.2 Global Precision Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Precision Cancer Diagnostic Tests Revenue
3.4 Global Precision Cancer Diagnostic Tests Market Concentration Ratio
3.4.1 Global Precision Cancer Diagnostic Tests Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Precision Cancer Diagnostic Tests Revenue in 2023
3.5 Precision Cancer Diagnostic Tests Key Players Head office and Area Served
3.6 Key Players Precision Cancer Diagnostic Tests Product Solution and Service
3.7 Date of Enter into Precision Cancer Diagnostic Tests Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Precision Cancer Diagnostic Tests Breakdown Data by Type
4.1 Global Precision Cancer Diagnostic Tests Historic Market Size by Type (2019-2024)
4.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Type (2025-2030)
5 Precision Cancer Diagnostic Tests Breakdown Data by Application
5.1 Global Precision Cancer Diagnostic Tests Historic Market Size by Application (2019-2024)
5.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Precision Cancer Diagnostic Tests Market Size (2019-2030)
6.2 North America Precision Cancer Diagnostic Tests Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Precision Cancer Diagnostic Tests Market Size by Country (2019-2024)
6.4 North America Precision Cancer Diagnostic Tests Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Precision Cancer Diagnostic Tests Market Size (2019-2030)
7.2 Europe Precision Cancer Diagnostic Tests Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Precision Cancer Diagnostic Tests Market Size by Country (2019-2024)
7.4 Europe Precision Cancer Diagnostic Tests Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Precision Cancer Diagnostic Tests Market Size (2019-2030)
8.2 Asia-Pacific Precision Cancer Diagnostic Tests Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Precision Cancer Diagnostic Tests Market Size by Region (2019-2024)
8.4 Asia-Pacific Precision Cancer Diagnostic Tests Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Precision Cancer Diagnostic Tests Market Size (2019-2030)
9.2 Latin America Precision Cancer Diagnostic Tests Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Precision Cancer Diagnostic Tests Market Size by Country (2019-2024)
9.4 Latin America Precision Cancer Diagnostic Tests Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Precision Cancer Diagnostic Tests Market Size (2019-2030)
10.2 Middle East & Africa Precision Cancer Diagnostic Tests Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Precision Cancer Diagnostic Tests Market Size by Country (2019-2024)
10.4 Middle East & Africa Precision Cancer Diagnostic Tests Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Precision Cancer Diagnostic Tests Introduction
11.1.4 Abbott Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Detail
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Precision Cancer Diagnostic Tests Introduction
11.2.4 Agilent Technologies Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.2.5 Agilent Technologies Recent Development
11.3 Becton Dickinson and Company
11.3.1 Becton Dickinson and Company Company Detail
11.3.2 Becton Dickinson and Company Business Overview
11.3.3 Becton Dickinson and Company Precision Cancer Diagnostic Tests Introduction
11.3.4 Becton Dickinson and Company Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.3.5 Becton Dickinson and Company Recent Development
11.4 Bio-Rad Laboratories
11.4.1 Bio-Rad Laboratories Company Detail
11.4.2 Bio-Rad Laboratories Business Overview
11.4.3 Bio-Rad Laboratories Precision Cancer Diagnostic Tests Introduction
11.4.4 Bio-Rad Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.4.5 Bio-Rad Laboratories Recent Development
11.5 Biocartis N.V.
11.5.1 Biocartis N.V. Company Detail
11.5.2 Biocartis N.V. Business Overview
11.5.3 Biocartis N.V. Precision Cancer Diagnostic Tests Introduction
11.5.4 Biocartis N.V. Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.5.5 Biocartis N.V. Recent Development
11.6 Biocept
11.6.1 Biocept Company Detail
11.6.2 Biocept Business Overview
11.6.3 Biocept Precision Cancer Diagnostic Tests Introduction
11.6.4 Biocept Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.6.5 Biocept Recent Development
11.7 bioMerieux SA
11.7.1 bioMerieux SA Company Detail
11.7.2 bioMerieux SA Business Overview
11.7.3 bioMerieux SA Precision Cancer Diagnostic Tests Introduction
11.7.4 bioMerieux SA Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.7.5 bioMerieux SA Recent Development
11.8 Canon Medical Systems Corporation
11.8.1 Canon Medical Systems Corporation Company Detail
11.8.2 Canon Medical Systems Corporation Business Overview
11.8.3 Canon Medical Systems Corporation Precision Cancer Diagnostic Tests Introduction
11.8.4 Canon Medical Systems Corporation Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.8.5 Canon Medical Systems Corporation Recent Development
11.9 Cynvenio Biosystems
11.9.1 Cynvenio Biosystems Company Detail
11.9.2 Cynvenio Biosystems Business Overview
11.9.3 Cynvenio Biosystems Precision Cancer Diagnostic Tests Introduction
11.9.4 Cynvenio Biosystems Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.9.5 Cynvenio Biosystems Recent Development
11.10 Danaher Corporation
11.10.1 Danaher Corporation Company Detail
11.10.2 Danaher Corporation Business Overview
11.10.3 Danaher Corporation Precision Cancer Diagnostic Tests Introduction
11.10.4 Danaher Corporation Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.10.5 Danaher Corporation Recent Development
11.11 Epigenomics AG
11.11.1 Epigenomics AG Company Detail
11.11.2 Epigenomics AG Business Overview
11.11.3 Epigenomics AG Precision Cancer Diagnostic Tests Introduction
11.11.4 Epigenomics AG Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.11.5 Epigenomics AG Recent Development
11.12 Exosome Diagnostics
11.12.1 Exosome Diagnostics Company Detail
11.12.2 Exosome Diagnostics Business Overview
11.12.3 Exosome Diagnostics Precision Cancer Diagnostic Tests Introduction
11.12.4 Exosome Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.12.5 Exosome Diagnostics Recent Development
11.13 Foundation Medicine
11.13.1 Foundation Medicine Company Detail
11.13.2 Foundation Medicine Business Overview
11.13.3 Foundation Medicine Precision Cancer Diagnostic Tests Introduction
11.13.4 Foundation Medicine Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.13.5 Foundation Medicine Recent Development
11.14 General Electric Company
11.14.1 General Electric Company Company Detail
11.14.2 General Electric Company Business Overview
11.14.3 General Electric Company Precision Cancer Diagnostic Tests Introduction
11.14.4 General Electric Company Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.14.5 General Electric Company Recent Development
11.15 Genomic Health
11.15.1 Genomic Health Company Detail
11.15.2 Genomic Health Business Overview
11.15.3 Genomic Health Precision Cancer Diagnostic Tests Introduction
11.15.4 Genomic Health Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.15.5 Genomic Health Recent Development
11.16 Hologic
11.16.1 Hologic Company Detail
11.16.2 Hologic Business Overview
11.16.3 Hologic Precision Cancer Diagnostic Tests Introduction
11.16.4 Hologic Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.16.5 Hologic Recent Development
11.17 Illumina
11.17.1 Illumina Company Detail
11.17.2 Illumina Business Overview
11.17.3 Illumina Precision Cancer Diagnostic Tests Introduction
11.17.4 Illumina Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.17.5 Illumina Recent Development
11.18 Menarini Silicon Biosystems SpA
11.18.1 Menarini Silicon Biosystems SpA Company Detail
11.18.2 Menarini Silicon Biosystems SpA Business Overview
11.18.3 Menarini Silicon Biosystems SpA Precision Cancer Diagnostic Tests Introduction
11.18.4 Menarini Silicon Biosystems SpA Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.18.5 Menarini Silicon Biosystems SpA Recent Development
11.19 Myriad Genetics
11.19.1 Myriad Genetics Company Detail
11.19.2 Myriad Genetics Business Overview
11.19.3 Myriad Genetics Precision Cancer Diagnostic Tests Introduction
11.19.4 Myriad Genetics Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.19.5 Myriad Genetics Recent Development
11.20 NanoString Technologies
11.20.1 NanoString Technologies Company Detail
11.20.2 NanoString Technologies Business Overview
11.20.3 NanoString Technologies Precision Cancer Diagnostic Tests Introduction
11.20.4 NanoString Technologies Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.20.5 NanoString Technologies Recent Development
11.21 Ortho Clinical Diagnostics
11.21.1 Ortho Clinical Diagnostics Company Detail
11.21.2 Ortho Clinical Diagnostics Business Overview
11.21.3 Ortho Clinical Diagnostics Precision Cancer Diagnostic Tests Introduction
11.21.4 Ortho Clinical Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.21.5 Ortho Clinical Diagnostics Recent Development
11.22 QIAGEN N.V.
11.22.1 QIAGEN N.V. Company Detail
11.22.2 QIAGEN N.V. Business Overview
11.22.3 QIAGEN N.V. Precision Cancer Diagnostic Tests Introduction
11.22.4 QIAGEN N.V. Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.22.5 QIAGEN N.V. Recent Development
11.23 Randox Laboratories Ltd.
11.23.1 Randox Laboratories Ltd. Company Detail
11.23.2 Randox Laboratories Ltd. Business Overview
11.23.3 Randox Laboratories Ltd. Precision Cancer Diagnostic Tests Introduction
11.23.4 Randox Laboratories Ltd. Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.23.5 Randox Laboratories Ltd. Recent Development
11.24 Roche Holding AG
11.24.1 Roche Holding AG Company Detail
11.24.2 Roche Holding AG Business Overview
11.24.3 Roche Holding AG Precision Cancer Diagnostic Tests Introduction
11.24.4 Roche Holding AG Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.24.5 Roche Holding AG Recent Development
11.25 Royal Philips N.V.
11.25.1 Royal Philips N.V. Company Detail
11.25.2 Royal Philips N.V. Business Overview
11.25.3 Royal Philips N.V. Precision Cancer Diagnostic Tests Introduction
11.25.4 Royal Philips N.V. Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.25.5 Royal Philips N.V. Recent Development
11.26 Siemens AG
11.26.1 Siemens AG Company Detail
11.26.2 Siemens AG Business Overview
11.26.3 Siemens AG Precision Cancer Diagnostic Tests Introduction
11.26.4 Siemens AG Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.26.5 Siemens AG Recent Development
11.27 Thermo Fisher Scientific
11.27.1 Thermo Fisher Scientific Company Detail
11.27.2 Thermo Fisher Scientific Business Overview
11.27.3 Thermo Fisher Scientific Precision Cancer Diagnostic Tests Introduction
11.27.4 Thermo Fisher Scientific Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.27.5 Thermo Fisher Scientific Recent Development
11.28 Vela Diagnostics
11.28.1 Vela Diagnostics Company Detail
11.28.2 Vela Diagnostics Business Overview
11.28.3 Vela Diagnostics Precision Cancer Diagnostic Tests Introduction
11.28.4 Vela Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2019-2024)
11.28.5 Vela Diagnostics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
